Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inpatient Outcomes of Pancreatic Cancer Surgery in Patients with Coronary Artery Disease.

Cancers·2026
Same author

Racial and Ethnic Disparities in the Management and Outcomes of Acute Myocardial Infarction Complicated by Ventricular Arrhythmias.

Journal of clinical medicine·2026
Same author

A sinGle-arm phase II study to assess efficacy, tOxicity, and quAlity of life following 27Gy in 6 fractions palliative intensity modulated radiotherapy with early integration of palliative care (GOAL27-6).

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Cardiogenic Shock With Acute Myocardial Infarction Among Older Adults in the United States.

JACC. Advances·2025
Same author

Comparative outcomes of percutaneous coronary intervention in ST-elevation myocardial infarction: an analysis by infarct-related coronary artery.

Proceedings (Baylor University. Medical Center)·2025
Same author

Targeting Triglycerides: The Rise of Apolipoprotein C3 and Angiopoietin-Like Protein 3 Inhibitors.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2025

Related Experiment Video

Updated: May 22, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Current oral antiplatelets: focus update on prasugrel.

Jinu John1, Santhosh K G Koshy

  • 1Maimonides Medical Center, Brooklyn, NY, USA.

Journal of the American Board of Family Medicine : JABFM
|May 10, 2012
PubMed
Summary

Prasugrel effectively reduces ischemic events in acute coronary syndrome (ACS) patients but increases bleeding risk, particularly in elderly or high-risk individuals. Further research aims for potent antiplatelet therapies with improved safety profiles.

More Related Videos

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

Related Experiment Videos

Last Updated: May 22, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

Area of Science:

  • Cardiology
  • Pharmacology
  • Thrombosis

Background:

  • Platelet activation and aggregation are key in acute coronary syndrome (ACS) pathogenesis.
  • Platelet inhibition is the cornerstone of ACS treatment, with greater inhibition linked to better outcomes.
  • Drug development focuses on potent platelet aggregation inhibitors.

Purpose of the Study:

  • To evaluate the efficacy and safety of prasugrel, a potent antiplatelet agent, in ACS patients.
  • To compare dual antiplatelet therapy with prasugrel plus aspirin versus clopidogrel plus aspirin.
  • To identify patient subgroups at higher risk for bleeding complications with prasugrel.

Main Methods:

  • Clinical evaluation of prasugrel's antiplatelet effects.
  • Comparison of ischemic outcomes between prasugrel/aspirin and clopidogrel/aspirin regimens.
  • Analysis of bleeding risk factors associated with prasugrel use.

Main Results:

  • Prasugrel plus aspirin reduces ischemic outcomes compared to clopidogrel plus aspirin.
  • Prasugrel, as a potent inhibitor, increases bleeding risk, especially in specific patient populations.
  • Elderly patients (≥75 years), those weighing ≥60 kg, and patients with a history of stroke or TIA face elevated bleeding risks.

Conclusions:

  • Prasugrel offers improved ischemic event reduction in ACS but necessitates careful consideration of bleeding risks.
  • Patient selection is crucial to mitigate bleeding complications associated with potent antiplatelet therapy.
  • Ongoing research seeks novel antiplatelets balancing efficacy and safety to minimize bleeding events.